Beam Therapeutics Inc. (BMV:BEAM)

Market Cap	34.92B
Revenue (ttm)	1.30B
Net Income (ttm)	-7.92B
Shares Out	n/a
EPS (ttm)	-94.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	140
Average Volume	1,321
Open	328.20
Previous Close	392.00
Day's Range	328.20 - 328.20
52-Week Range	310.00 - 590.00
Beta	n/a
RSI	26.43
Earnings Date	May 7, 2025

About Beam Therapeutics

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sic...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Employees: 483
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: BEAM

Financial Performance

In 2024, Beam Therapeutics's revenue was $63.52 million, a decrease of -83.18% compared to the previous year's $377.71 million. Losses were -$376.74 million, 184.3% more than in 2023.

Financial numbers in USD